Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 795-803

  Karczmarczyk, Urszula ^a   Garnuszek, Piotr ^a   Maurin, Michał ^a   Di Gialleonardo, Valentina ^b,c   Galli, Filippo ^b   Signore, Alberto ^b,c   Mikołajczak, Renata ^d  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

Biodistribution; HYNIC; Inflammation imaging; Radiolabelling; RhIL 2 peptide; Technetium 99m

Indexed keywords

2 SULFOBENZALDEHYDE; ANTIOXIDANT; BENZALDEHYDE DERIVATIVE; BUFFER; HYDRAZINONICOTINAMIDE; NICOTINAMIDE DERIVATIVE; NICOTINIC ACID; RECOMBINANT INTERLEUKIN 2; STANNOUS CHLORIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HYDRAZINONICTINAMIDE; INTERLEUKIN 2; NICOTINAMIDE; RECOMBINANT PROTEIN; TECHNETIUM COMPLEX; TECHNETIUM TC 99M INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG SPECIFICITY; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCESS OPTIMIZATION; QUALITY CONTROL; RADIOCHEMISTRY; RAT; SWISS WEBSTER MOUSE; WISTAR RAT; ANIMAL; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; LYMPHOCYTE; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; LYMPHOCYTES; MALE; MICE; NIACINAMIDE; ORGANOTECHNETIUM COMPOUNDS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 77957013981     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.04.013     Document Type: Article

References (33)

1. van der Laken C.J., Boerman O.C., Oyen W.J.G., van der Ven M.T.P., van der Meer J.W.M., Corsten F.H. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: a comparative study. Eur J Nucl Med 1998, 25:347-352.
2. Signore A., D'Alessandria C., Annovazzi A., Scopinaro F. Radiolabelled cytokines for imaging chronic inflammation. Braz Arch Biol Technol 2002, 45:15-23.
3. Lowenthal J.W., MacDonald H.R. Binding and internalization of interleukin-1 by T-cells. J Exp Med 1986, 164:1060-1074.
4. van der Laken C.J., Boerman O.C., Oyen W.J.G., van der Ven M.T.P., Claessens R.A.M.J., Van der Meer J.W.M., et al. Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. Eur J Nucl Med 1995, 22:1249-1255.
5. Van der Laken C.J., Boerman O.C., Oyen W.J.G., Van der Ven M.T.P., Laverman P., Van der Meer J.W.M., et al. Targeting inflammation with radiolabeled interleukin-1 and other cytokines in various mouse models. Nucl Med Commun 1997, 18:478. [Abstract].
6. 99mTc-labeled interleukin-8. J Nucl Med 2001, 42:117-123.
7. Van der Laken C.J., Boerman O.C., Oyen W.J.G., Van der Ven M.T.P., Van der Meer J.W.M., Corstens F.H.M. Radiolabeled interleukin-8 specific scintigraphic detection of infection within a few hours. J Nucl Med 2000, 41:463-469.
8. 99mTc-Interleukin-8 for imaging acute osteomyelitis. J Nucl Med 2001, 42:1257-1264.
9. 123I-Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity. J Pediatr Endocrinol Metab 1996, 9:139-144.
10. Signore A., Chianelli M., Annovazzi A., Rossi M., Maiuri L., Greco M., et al. Imaging active lymphocytic infiltration in coeliatic disease with iodine-123-interleukin-2 ant its response to diet. Eur J Nucl Med 2000, 27:18-24.
11. 123I-Interleukin-2 scintigraphy for the in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000, 41:242-249.
12. 125iodine labeled interleukin-2 in the pancreas of NOD mice. J Autoimmun 2001, 17:281-287.
13. 99mTc-Interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. Eur J Nucl Med Mol Imaging 2008, 35(12):2286-2293.
14. Abbs I.C., Pratt J.R., Dallman M.J., Sacks S.H. Analysis of activated T cell infiltrated in rat renal allografts by gamma camera imaging after injection of 123-iodine-interleukin 2. Transpl Immunol 1993, 1:45-51.
15. 99mTc-IL2 Scintigraphy in patients with cutaneous melanoma: detection of lymphocytic infiltration. Eur J Nucl Med 1998, 25:896. [Abstract].
16. 123I-interleukin-2 labelling procedure and animal studies. Nucl Med Commun 1992, 13:713-722.
17. Signore A. Interleukin-2 scintigraphy: an overview. Nucl Med Commun 1999, 20:938.
18. 123I-IL-2 for in vivo detection of activated lymphocytes: a scintigraphic and histological study in coeliac patients. Eur J Nucl Med 1995, 22:794. [Abstract].
19. 123I Labelled interleukin-2 in Crohn's disease: assessment of activity state and therapy follow-up. Eur J Nucl Med 1995, 22:795. [Abstract].
20. Chianelli M., Signore A., Fritzberg A.R., Macher S.J. The development of technetium-99m labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997, 24:579-586.
21. 123I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. Perit Dial Int 2009, 29(5):568-574.
22. Rennen H.J.J.M., Boerman O.C., Koenders E.B., Oyen W.J.G., Corstens F.H.M. Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. Nucl Med Biol 2000, 7:599-604.
23. D'Alessandria C., di Gialleonardo V., Chianelli M., Mather S.J., de Vries E.F., Scopinaro F., et al. Synthesis and optimization of the labeling procedure of (99m)Tc-Hynic-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol 2009, [Epub ahead of print]. 10.1007/s11307-009-0285-1.
24. Abrams M.J., Juweid M., ten Kate C.I., Schwarz D.A., Hauser M.M., Gaul F.E., et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990, 31:2022-2028.
25. Cadee J.A., de Groot C.J., Jiskoot W., den Otter W., Hennink W.E. Release of recombinant human interleukin-2 from dextran-based hydrogels. J Controlled Release 2002, 78:1-13.
26. King T.P., Zhao S.W., Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry 1986, 25:5774-5779.
27. Rennen H.J.J.M., van Eerd J.E., Oyen W.J.G., Corstens F.H.M., Edwards D.S., Boerman O.C. Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled interleukin-8 in detection of infection. Bioconjugate Chem 2002, 13:370-377.
28. 99mTc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. Nucl Med Biol 2001, 28:155-164.
29. King R.C., Bashir-Uddin Surfraz M., Biagini S.C.G., Blower F.J., Mather S.J. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalton Trans 2007, 21:4998-5007.
30. Gibbons J.A., Luo Z.P., Hannon E.R., Braeckman R.A., Young J.D. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats. J Pharmacol Exp Ther 1995, 272:119-125.
31. Chen S.A., Sawchuk R.J., Brundage R.C., Horvath C.h., Mendenhall H.V., Gunther R.A., et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 2000, 293:248-259.
32. 99mTc-HYNIC-IL-2 scintigraphy to detect and quantify IL-2R positive cells in atherosclerotic plaques within carotid arteries in patients treated with maintenance dialysis. Q J Nucl Med Mol Imaging 2008, 52(suppl. 1):10.
33. 99mTc-HYNIC-IL-2 scintigraphy in the end-stage renal disease patients. Eur J Nucl Med Mol Imaging 2008, 35(suppl. 2):S385.